Imc Chicago, LLC Novavax Inc Transaction History

Imc Chicago, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 12, 2024	BUY	$3.76 - $6.02 $62,682 - $100,359	16,671 Added 32.28%	68,322 $326,000
Q4 2023 Feb 09, 2024	BUY	$4.8 - $7.67 $247,924 - $396,163	51,651 New	51,651 $247,000
Q2 2022 Aug 05, 2022	SELL	$36.28 - $75.29 $1.52 Million - $3.15 Million	-41,853 Closed	0 $0
Q1 2022 Apr 19, 2022	BUY	$69.73 - $142.9 $363,432 - $744,794	5,212 Added 14.22%	41,853 $3.08 Million
Q4 2021 Feb 08, 2022	SELL	$134.56 - $217.97 $2.25 Million - $3.65 Million	-16,745 Reduced 31.37%	36,641 $5.24 Million
Q3 2021 Nov 05, 2021	BUY	$177.8 - $270.58 $9.49 Million - $14.4 Million	53,386 New	53,386 $11.1 Million
Q2 2021 Aug 06, 2021	SELL	$121.0 - $257.67 $1.7 Million - $3.63 Million	-14,087 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$112.98 - $319.93 $1.59 Million - $4.51 Million	14,087 New	14,087 $2.55 Million
Q3 2020 Nov 17, 2020	SELL	$79.44 - $178.51 $1.2 Million - $2.7 Million	-15,106 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$13.86 - $83.61 $209,369 - $1.26 Million	15,106 New	15,106 $1.26 Million

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $666M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Imc Chicago, LLC, based on Form 13F filings with the SEC.

Stay updated on Imc Chicago, LLC with notifications on news.